



**NMS Labs**

**CONFIDENTIAL**

200 Welsh Road, Horsham, PA 19044-2208  
Phone: (215) 657-4900 Fax: (215) 657-2972  
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

**Demo Report**

**Report Issued** 03/30/2020 11:50  
**Last Report Issued** 09/26/2014 12:24

**88888**  
Clinical Example Report  
Attn: Example Reports  
200 Welsh Road  
Horsham, PA 19044

**Patient Name** 1220SP  
**Patient ID** 1220SP  
**Chain** 14002768  
**Age** Not Given **DOB** Not Given  
**Gender** Not Given  
**Workorder** 14002768  
**Received** 09/26/2014 12:12

**Sample ID** 14002768-001  
**Matrix** Serum or Plasma  
**Patient Name** 1220SP  
**Patient ID** 1220SP  
**Container Type** Clear vial

**Collect Dt/Tm** Not Given  
**Source** Not Given

**Approx Vol/Weight** Not Given

**Receipt Notes** None Entered

| Analysis and Comments | Result | Units | Reporting Limit | Notes |
|-----------------------|--------|-------|-----------------|-------|
|-----------------------|--------|-------|-----------------|-------|

**1220SP Chlorpropamide, Serum/Plasma**

Analysis by High Performance Liquid Chromatography/  
Tandem Mass Spectrometry (LC-MS/MS)

|                |               |        |      |  |
|----------------|---------------|--------|------|--|
| Chlorpropamide | None Detected | mcg/mL | 0.10 |  |
|----------------|---------------|--------|------|--|

Synonym(s): Diabinese®

Peak plasma concentrations of approximately  
75 - 360 mcg/mL were achieved 2 hours following  
chronic daily doses of 250 - 1000 mg.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.